PARP inhibitors and radiometabolic approaches in metastatic castration-resistant prostate cancer: what's now, what's new, and what's coming?

A Marchetti, M Rosellini, G Nuvola, E Tassinari… - Cancers, 2022 - mdpi.com
Simple Summary Prostate cancer still represents an important health problem in men,
considering its high frequency. Over the last decade, novel treatment options have emerged …

[HTML][HTML] Cancer de prostate métastatique résistant à la castration et inhibiteurs de PARP: de la génomique tumorale aux nouvelles associations thérapeutiques

S Oudard, MO Timsit, D Maillet, G Mouillet… - Bulletin du …, 2024 - Elsevier
Résumé Le cancer de la prostate au stade métastatique résistant à la castration reste létal et
constitue un défi thérapeutique. Les stratégies actuelles s' orientent vers la personnalisation …

[HTML][HTML] PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer

N Gordon, PT Gallagher, NP Neupane, AC Mandigo… - bioRxiv, 2023 - ncbi.nlm.nih.gov
Prostate cancer (PCa) is the second leading cause of cancer death for men in the United
States. While organ-confined disease has reasonable expectation of cure, metastatic PCa is …

[HTML][HTML] Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report

TR McFarland, CE Tandar, N Agarwal… - Cancer Treatment and …, 2021 - Elsevier
Cancers with mutations in BRCA2 have defective DNA repair capacity which is potentially
targetable with poly-ADP (ribose) polymera se (PARP) inhibitors such as olaparib and …

Prostate Cancer and DNA Genes Repair: What Should an Oncologist Know?–A Narrative Review

FS de Azevedo, LM de Santana Sá… - … Indonesian Journal of …, 2023 - hmpublisher.com
Prostate cancer is a very prevalent disease in men, especially in Western countries. The
treatment of this neoplasm, both localized and locally advanced, is based on the clinical risk …